You have full text access to this OnlineOpen article

GA2LEN (Global Allergy and Asthma European Network) addresses the allergy and asthma ‘epidemic’

  1. J. Bousquet1,
  2. P. G. Burney2,
  3. T. Zuberbier3,
  4. P. v. Cauwenberge4,
  5. C. A. Akdis5,
  6. C. Bindslev-Jensen6,
  7. S. Bonini7,
  8. W. J. Fokkens8,
  9. F. Kauffmann9,
  10. M. L. Kowalski10,
  11. K. Lodrup-Carlsen11,
  12. J. Mullol12,
  13. E. Nizankowska-Mogilnicka13,
  14. N. Papadopoulos14,
  15. E. Toskala15,
  16. M. Wickman16,
  17. J. Anto17,
  18. N. Auvergne18,
  19. C. Bachert19,
  20. P. J. Bousquet20,
  21. B. Brunekreef21,
  22. G. W. Canonica22,
  23. K. H. Carlsen23,
  24. M. Gjomarkaj24,
  25. T. Haahtela25,
  26. P. Howarth26,
  27. G. Lenzen27,
  28. J. Lotvall28,
  29. K. Radon29,
  30. J. Ring30,
  31. M. Salapatas31,
  32. H. J. Schünemann32,
  33. A. Szczecklik13,
  34. A. Todo-Bom33,
  35. E. Valovirta34,
  36. E. Von Mutius35,
  37. J. P. Zock17

Article first published online: 7 APR 2009

DOI: 10.1111/j.1398-9995.2009.02059.x

Issue

Allergy

Allergy

Volume 64, Issue 7, pages 969–977, July 2009

Additional Information

How to Cite

Bousquet, J., Burney, P. G., Zuberbier, T., Cauwenberge, P. v., Akdis, C. A., Bindslev-Jensen, C., Bonini, S., Fokkens, W. J., Kauffmann, F., Kowalski, M. L., Lodrup-Carlsen, K., Mullol, J., Nizankowska-Mogilnicka, E., Papadopoulos, N., Toskala, E., Wickman, M., Anto, J., Auvergne, N., Bachert, C., Bousquet, P. J., Brunekreef, B., Canonica, G. W., Carlsen, K. H., Gjomarkaj, M., Haahtela, T., Howarth, P., Lenzen, G., Lotvall, J., Radon, K., Ring, J., Salapatas, M., Schünemann, H. J., Szczecklik, A., Todo-Bom, A., Valovirta, E., Von Mutius, E. and Zock, J. P. (2009), GA2LEN (Global Allergy and Asthma European Network) addresses the allergy and asthma ‘epidemic’. Allergy, 64: 969–977. doi: 10.1111/j.1398-9995.2009.02059.x

Author Information

  1. 1

    University Hospital and INSERM U780, Hôpital Arnaud de Villeneuve, Montpellier, France

  2. 2

    National Heart and Lung Institute, Imperial College, Respiratory Epidemiology and Public Health, London, UK

  3. 3

    Allergy Centre Charité, Charité– Universitätsmedizin Berlin, Germany

  4. 4

    Ghent University, Ghent, Belgium

  5. 5

    Swiss Institute of Allergy and Asthma Research (SIAF), Davos, Switzerland

  6. 6

    Odense University Hospital, Denmark

  7. 7

    Second University of Naples, INMM-CNR, Rome, Italy

  8. 8

    Academic Medical Center, Amsterdam, the Netherlands

  9. 9

    Inserm U780, Villejuif, France

  10. 10

    Medical University of Lodz, Poland

  11. 11

    Department of Paediatrics, Ullevål University Hospital and The Faculty of Medicine, University of Oslo, Norway

  12. 12

    Hospital Clinic – IDIBAPS, Barcelona, Catalonia, Spain

  13. 13

    Jagiellonian University School of Medicine, Krakow, Poland

  14. 14

    Allergy Research Center, University of Athens, Greece

  15. 15

    Helsinki University Hospital and Finnish Institute of Occupational Health, Haartmanink, Helsinki, Finland

  16. 16

    Sach’s Children’s Hospital, Stockholm, Institute of Environmental Medicine, Karolinska Institutet, Stockholm

  17. 17

    Unitat de Recerca Respiratòria i Ambiental, Institut Municipal d’Investigacions Mèdiques (IMIM), Barcelona, Spain

  18. 18

    Interel, Brussels, Belgium

  19. 19

    UZG, University Hospital Ghent, Belgium

  20. 20

    University Hospital, Nîmes, France

  21. 21

    University of Utrecht, the Netherlands

  22. 22

    Allergy & Respiratory Diseases Clinic, University of Genova, Italy

  23. 23

    Voksentoppen, Rikshospitalet, Faculty of Medicine, University of Oslo, Norwegian School of Sport Science, Norway

  24. 24

    Consiglio Nazionale delle Ricerche CNR – Istituto di Biomedicina e Immunologia Molecolare, Palermo, Italy

  25. 25

    Skin and Allergy Hospital, Helsinki University Hospital, Finland

  26. 26

    University of Southampton, England

  27. 27

    InsermTransfert, Paris, France

  28. 28

    University of Gothenburg, Sweden

  29. 29

    Institute for Occupational and Environmental Medicine, Ludwig-Maximilians-University, Munich, Germany

  30. 30

    Technische Universität München, Germany

  31. 31

    EFA (European Federation of Allergy and Airways Diseases Patients Associations), Brussels, Belgium

  32. 32

    McMaster University Health Sciences Centre, Hamilton, Canada

  33. 33

    Immunoallergology Department, Coimbra University Hospital, Portugal

  34. 34

    Turku Allergy Center, Turku, Finland

  35. 35

    Ludwig Maximilians Universität, München, Germany

*J. Bousquet Hôpital Arnaud de Villeneuve INSERM U780 Service Maladies Respiratoires 34295 Montpellier Cedex 5 France

Publication History

  1. Issue published online: 1 JUN 2009
  2. Article first published online: 7 APR 2009
  3. Accepted for publication 3 February 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (132K)

Keywords:

  • allergy;
  • asthma;
  • European Union;
  • Global Allergy and Asthma European Network

Allergic diseases represent a major health problem in Europe. They are increasing in prevalence, severity and costs. The Global Allergy and Asthma European Network (GA2LEN), a Sixth EU Framework Program for Research and Technological Development (FP6) Network of Excellence, was created in 2005 as a vehicle to ensure excellence in research bringing together research and clinical institutions to combat fragmentation in the European research area and to tackle Allergy in its globality. The Global Allergy and Asthma European Network has benefited greatly from the voluntary efforts of researchers who are strongly committed to this model of pan-European collaboration. The network was organized in order to increase networking for scientific projects in allergy and asthma around Europe and to make GA2LEN the world leader in the field. Besides these activities, research has also been carried out and the first papers are being published. Achievements of the Global Allergy and Asthma European Network can be grouped as follows: (i) those for a durable infrastructure built up during the project phase, (ii) those which are project-related and based on these novel infrastructures, and (iii) the development and implementation of guidelines. The major achievements of GA2LEN are reported in this paper.

View Full Article (HTML) Get PDF (132K)